Ryan Specialty Group (RYAN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
17 Mar, 2026Voting matters and shareholder proposals
Election of five director nominees: David P. Bolger, Michael G. Bungert, Francesca Comelli, Nicholas D. Cortezi, and Anthony J. Kuczinski, with board recommending a vote for each.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, recommended for approval.
Advisory vote to approve compensation of named executive officers (say-on-pay), recommended for approval.
Board of directors and corporate governance
Five director nominees are presented for election at the annual meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included as a proposal, with board recommending approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ryan Specialty Group
- A dual-platform specialty insurer pairs market leadership with durable growth and disciplined investment.RYAN
Investor presentation - Revenue and adjusted EPS grew despite pricing pressure; FY margin guidance improved to ~50 bps down.RYANQ3 2026
- Q2 2026 revenue up 7.2% to $916.6M, strong margins, and $284.5M returned to shareholders.RYANQ2 2026
- Scale, innovation, and disciplined growth drive resilience and leadership in specialty insurance.RYAN46th Annual William Blair Growth Stock Conference
- Revenue up 15.2% to $795.2M, organic growth 11.8%, net income $40.6M, margin pressure ahead.RYANQ1 2026
- Record revenue, expanded shareholder rights, and a focus on performance-based leadership mark 2025.RYANProxy Filing
- Revenue up 18.8% and net income up 40.8%, with margin and guidance both raised.RYANQ2 2024
- Q3 revenue up 20.5%, net income up 82.4%, and adjusted EBITDAC up 29.4% year-over-year.RYANQ3 2024
- Revenue up 25% and adjusted EBITDAC up 27.5%, but net income impacted by non-cash tax expense.RYANQ1 2025